The Effect of Dalteparin, a Kind of Low Molecular Weight Heparin, on Lung Adenocarcinoma A549 Cell Line In Vitro

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Investigation

• Publication date

  2008-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/07357900801935631PMID 18608211
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiangiogenic and Apoptotic Properties of a Novel Amphiphilic Folate-Heparin-Lithocholate Derivative Having Cellular Internality for Cancer Therapy

  2007cited by this paper
• In Vitro Investigation of the Apoptotic Effect of Heparin on Lymphoblasts by Using Flow Cytometric DNA Analysis and Fluorometric Caspase-3 and -8 Activities

  2007cited by this paper
• Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

  2007cited by this paper
• The effect of low molecular weight heparin on survival in patients with advanced malignancy.

  2005cited by this paper
• Cyclin-Dependent Kinase Inhibitor p27Kip1, But Not p21WAF1/Cip1, Is Required for Inhibition of Hypoxia-Induced Pulmonary Hypertension and Remodeling by Heparin in Mice

  2005cited by this paper
• Generic low-molecular-weight heparins: some practical considerations.

  2004cited by this paper
• Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death.

  2004cited by this paper
• Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.

  2004cited by this paper
• A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer

  2004cited by this paper
• Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells

  2004cited by this paper
• Poly(β-amino ester)s Promote Cellular Uptake of Heparin and Cancer Cell Death

  2004cited by this paper
• IN VITRO DETERMINATION OF THE APOPTOTIC EFFECT OF HEPARIN ON LYMPHOBLASTS USING DNA ANALYSIS AND MEASUREMENTS OF Fas AND Bcl-2 PROTEINS BY FLOW CYTOMETRY

  2004cited by this paper
• Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

  2004cited by this paper
• The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity.

  2003cited by this paper
• The low molecular weight heparins dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model.

  2003cited by this paper
• Cell cycle deregulation in B-cell lymphomas.

  2003cited by this paper
• Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration.

  2002cited by this paper
• Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line.

  2002cited by this paper
• Overexpression of p27Kip1 induces growth arrest and apoptosis in an oral cancer cell line

  2002cited by this paper
• Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.

  2002cited by this paper
• Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis

  2001cited by this paper
• Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21

  2001cited by this paper
• A degradation signal located in the C‐terminus of p21WAF1/CIP1 is a binding site for the C8 α‐subunit of the 20S proteasome

  2001cited by this paper
• The complex effects of heparins on cancer progression and metastasis in experimental studies.

  2001cited by this paper
• The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells.

  2000cited by this paper
• Regulation of the Cdk inhibitor p27 and its deregulation in cancer

  2000cited by this paper
• Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.

  2000cited by this paper
• Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro.

  2000cited by this paper
• CDK inhibitors: positive and negative regulators of G1-phase progression.

  1999cited by this paper
• Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27.

  1999cited by this paper
• SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

  1999cited by this paper
• Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: Results of a preliminary in vitro study

  1999cited by this paper
• Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells

  1999cited by this paper
• Transcriptional regulation of the p21((WAF1/CIP1)) gene.

  1999cited by this paper
• Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

  1998cited by this paper
• Retinoblastoma protein recruits histone deacetylase to repress transcription

  1998cited by this paper
• Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

  1997cited by this paper
• Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation

  1997cited by this paper
• p53 in growth control and neoplasia.

  1996cited by this paper
• Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture.

  1995cited by this paper
• Mammalian antiproliferative signals and their targets.

  1995cited by this paper
• Unfractionated heparin and low molecular weight heparin do not inhibit the growth of proliferating human arterial smooth muscle cells in culture.

  1995cited by this paper
• A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.

  1992cited by this paper
• Inhibition of BC3H-1 cell growth by heparin is related to decreased mitogenic signalling.

  1990cited by this paper
• Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury.

  1985cited by this paper
• Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: In Vivo Studies with Anticoagulant and Nonanticoagulant Heparin

  1980cited by this paper
• Suppression by heparin of smooth muscle cell proliferation in injured arteries

  1977cited by this paper

• The Anticoagulant and Nonanticoagulant Properties of Heparin

  2020cites this paper
• Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells

  2019cites this paper
• Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.

  2017cites this paper
• Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism

  2015cites this paper
• Biological Impact of Membranous Nanostructures

  2015cites this paper
• Identification of pro- and anti-proliferative oligosaccharides of heparins.

  2014cites this paper
• The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.

  2014cites this paper
• The mechanisms of nadroparin‐mediated inhibition of proliferation of two human lung cancer cell lines

  2012cites this paper
• Glycosaminoglycans and neuroprotection.

  2012cites this paper
• Heparin - A Century of Progress

  2012cites this paper
• Compositional Determinants of the Pharmacological Actions of Heparins

  2012cites this paper
• The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.

  2010cites this paper
• Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin.

  2009cites this paper
• Cancer and thrombosis: implications of published guidelines for clinical practice.

  2009cites this paper